Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02951819
Title A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Janssen Scientific Affairs, LLC

multiple myeloma


Bortezomib + Cyclophosphamide + Daratumumab + Dexamethasone

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.